Integrated penpulimab (a PD-1 inhibitor), anlotinib (an antiangiogenic targeted drug), nab-paclitaxel and gemcitabine as first-line regimen for metastatic pancreatic cancer: A multi-centered, randomized controlled trial (RCT-PAAG).    

派安普利单抗（PD-1 抑制剂）、安罗替尼（抗血管生成靶向药）、白蛋白结合型紫杉醇与吉西他滨联合作为转移性胰腺癌一线方案：一项多中心随机对照试验（RCT-PAAG）    

讲者：杜娟 | 南京鼓楼医院

Combining the albumin-bilirubin (ALBI) score and ECOG performance status for enhanced prognostication in advanced biliary tract cancer treated with durvalumab-based immunochemotherapy.

联合白蛋白-胆红素（ALBI）评分与 ECOG 体能状态，优化度伐利尤单抗为基础的免疫化疗治疗晚期胆道癌的预后评估

讲者：Chi-Chen Lan | 长庚纪念医院

Pathological complete response after systemic conversion therapy and curative resection in initially unresectable hepatocellular carcinoma: Feasibility of a tumor-free for drug-free strategy.

初始不可切除肝细胞癌经全身转化治疗联合根治性切除后的病理完全缓解：“无瘤即停药” 策略的可行性

讲者：王骏成 | 中山大学肿瘤防治中心

Efficacy and safety of durvalumab plus gemcitabine/cisplatin in combined hepatocellular-cholangiocarcinoma versus cholangiocarcinoma.

度伐利尤单抗联合吉西他滨 / 顺铂在混合型肝细胞 - 胆管癌与胆管癌中的疗效与安全性

讲者：Yu-Wei Hsu | 长庚纪念医院

External validation of MAGIC-D in Taiwanese patients with advanced biliary tract cancer receiving durvalumab and chemotherapy.    

MAGIC-D 模型在接受度伐利尤单抗联合化疗的台湾晚期胆道系统癌患者中的外部验证    

讲者：Chi-Lin Hsieh | 长庚纪念医院

Transarterial chemoembolization (TACE) combined with sintilimab and bevacizumab versus TACE alone in patients with Barcelona Clinic Liver Cancer stage B unresectable hepatocellular carcinoma: A retrospective, propensity score-matched analysis.

经动脉化疗栓塞（TACE）联合信迪利单抗与贝伐珠单抗 vs 单用 TACE 治疗巴塞罗那临床肝癌分期 B 期不可切除肝细胞癌：一项回顾性倾向评分匹配分析

讲者：蔡鸿杰 | 中山大学附属第一医院

Pattern of progression in advanced hepatocellular carcinoma treated with immunotherapy. 

免疫治疗下晚期肝细胞癌的进展模式    

讲者：Thomas Yau | 香港大学

A simple ABC score for prognosis stratification and treatment selection in advanced hepatocellular carcinoma.

用于晚期肝细胞癌预后分层与治疗选择的简易 ABC 评分    

讲者：Yung-Yeh Su | 国家卫生研究院

Toripalimab plus hepatic artery infusion chemotherapy in hepatocellular carcinoma patients of Barcelona Clinic Liver Cancer stage C: A biomolecular exploratory, phase Il trial.    

特瑞普利单抗联合肝动脉灌注化疗用于巴塞罗那临床肝癌C期肝细胞癌患者：一项生物分子探索性II期临床试验。

讲者：Rongce Zhao | 中山大学肿瘤防治中心

Optimizing the sequencing and timing of transarterial chemoembolization and systemic therapy in advanced hepatocellular carcinoma.    

优化经动脉化疗栓塞与系统式治疗在晚期肝细胞癌中的序贯与时机安排。 

讲者：黄莹莹 | 北京医院

Sequential transarterial chemoembolization and stereotactic body radiotherapy followed by immunotherapy using single tremelimumab regular interval durvalumab in locally advanced, unresectable HCC (START-FIT using STRIDE): A single-arm, phase Il, multi-centre study.    

序贯性经动脉化疗栓塞术联合体部立体定向放射治疗，随后采用单次tremelimumab联合固定间隔durvalumab免疫疗法治疗局部晚期不可切除肝细胞癌（START-FIT方案应用STRIDE策略）：一项单臂、II期、多中心临床研究。    

讲者：Chi Leung Chiang | 香港大学

Donafenib and sintilimab plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A phase Il, biomarker exploratory study (Dosin TACE).

多纳非尼与信迪利单抗联合经导管动脉化疗栓塞治疗不可切除肝细胞癌：一项II期生物标志物探索性研究（Dosin TACE）。

讲者：Xiaoyun Hu | 南方医科大学南方医院

Adjuvant sintilimab plus capecitabine in resected extrahepatic cholangiocarcinoma: Interim report of a single-arm, prospective phase Il study.

辅助性信迪利单抗联合卡培他滨治疗肝外胆管癌切除术后的中期报告：一项单臂前瞻性II期研究。

讲者：Jinxue Zhou | 郑州大学附属肿瘤医院

Sintilimab combined with lenvatinib versus hepatic artery infusion chemotherapy (HAIC) for neoadjuvant treatment of resectable hepatocellular carcinoma with high risk of recurrence: A prospective, two-arm, randomized, phase Il clinical study.

信迪利单抗联合仑伐替尼对比肝动脉灌注化疗（HAIC）用于可切除性肝细胞癌伴高复发风险患者的新辅助治疗：一项前瞻性、双臂、随机、II期临床研究。

讲者：Feng Fang | 天津医科大学肿瘤医院

Safety and efficacy of hepatic artery infusion chemotherapy (HAIC) or lenvatinib combined with sintlimab as neoadjuvant therapy for high recurrence risk resectable stage IB solitary hepatocellular carcinoma: A prospective, randomized, two-cohort, exploratory phase Il clinical study.    

肝动脉灌注化疗（HAIC）或仑伐替尼联合信迪利单抗作为高复发风险可切除IB期孤立性肝细胞癌新辅助治疗的安全性与有效性：一项前瞻性、随机、双队列、探索性II期临床研究。

讲者：Yunlong Cui | 天津医科大学肿瘤医院

Outcomes of sarcomatoid hepatocellular carcinoma patients treated with immunotherapy: A multi-institutional retrospective study.

肉瘤样肝细胞癌患者接受免疫治疗的疗效：一项多机构回顾性研究。

讲者：Tsung-Hao Liu | 台湾大学医学院

Early detection of hepatocellular carcinoma using red blood cell DNA signatures.

通过红细胞DNA特征早期检测肝细胞癌。

讲者：XIngyun Yao | 西湖大学生命科学学院

Real-world efficacy and safety of surufatinib in advanced neuroendocrine neoplasm.

索凡替尼在晚期神经内分泌肿瘤中的真实世界疗效与安全性。

讲者：Jiang Long | 上海市第一人民医院

Updated results of the phase 1/2 study of TSN1611, a highly selective KRAS G12D inhibitor, in patients with advanced solid tumors.

KRAS G12D高选择性抑制剂TSN1611在晚期实体瘤患者中的1/2期研究更新结果。

讲者：Jian Li | 北京大学肿瘤医院

Preoperative NALIRIFOX versus upfront surgery in high-risk resectable pancreatic cancer: A randomized, multi-center trial.

术前NALIRIFOX方案对比直接手术在高风险可切除胰腺癌中的疗效：一项随机多中心临床试验。

讲者：Shiwei Guo | 上海长海医院

摘要号：TPS607

Curative therapy after atezolizumab and bevacizumab treatment for unresectable hepatocellular carcinoma: A multinational retrospective study.

阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌后的根治性治疗：一项多国回顾性研究。

讲者：Yu-Yun Shao | 台湾大学医学院附设医院

备注：排名不分先后，按照摘要号进行排序

如有遗漏或任何问题，请给我们留言~